ALFA Finder| Revenue growth | 19.1% YoY |
|---|---|
| Margins | EBITDA margin improved to 31% from 28.7% YoY. |
| Demand visibility | Strong, driven by lifestyle diseases and health awareness. |
| Management confidence | High, citing resilient growth trajectory and operational momentum. |
Growth
Revenue rose 19.1% to Rs. 798 Cr; EBITDA up 28.7% to Rs. 247 Cr; PAT grew 27.2% to Rs. 170 Cr.
Outlook
Focusing on high-complexity portfolios and AI-powered diagnostics. Expanding reach into rural markets via GraminFit program.
Risks
Fragmented industry competition; structural shifts toward regular preventive testing require constant investment in digital infrastructure.
Last quarter's promises, checked
Delivered
- Guided early to mid-teens revenue growth → delivered 19.1% (= BEAT)
- Guided 27%-28% EBITDA margin → delivered 31.0% (= BEAT)
- Guided sustaining patient volume growth → delivered 8.2% (= BEAT)
Partly delivered
- Guided Rs. 100-120 Cr annual capex → Q1 cash position increased to Rs. 1,693 Cr (= PARTIAL)
Investor Presentation filed with BSE, NSE: LALPATHLAB. Summary written with AI assistance from the document.
Dr. Lal Pathlabs Ltd: key numbers
- Share price
- ₹2,008.80
- Market cap
- ₹33,717 Cr
- Revenue (annual)
- ₹2,763 Cr
- Net profit (annual)
- ₹504.8 Cr
- P/E (TTM)
- 57.8×Sector 54.7×
- Promoter holding
- 52.93%-0.26% QoQ
- FII holding
- 18.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Lal Pathlabs Ltd
All →Dr. Lal Pathlabs Annual General Meeting
Dr. Lal PathLabs issued a Postal Ballot Notice seeking member approval to appoint Ms. Vasuta Agarwal as Independent Director for a three-year term.
Dr. Lal Pathlabs Management Change
Dr. Lal Path Labs appointed Ms. Vasuta Agarwal as an additional Non-Executive Independent Director for three years from 4 November 2026. Her appointment is subject to member approval by postal ballot.
- Execution
- 36 months from 04-11-2026
Dr. Lal Pathlabs Capital Structure Change
Dr. Lal PathLabs will invest up to Rs 49.5 Crore in its wholly owned Dubai subsidiary, in tranches. Funds cover operations and further investment in Ghana's SHL.
- Value
- ₹49.50 Cr
- Execution
- Indicative completion by 31 March 2027, in tranches
Dr. Lal Pathlabs Dividend
Dr. Lal Path Labs approved a Rs 5 per share second interim dividend. Record date is November 11, 2026; payment by December 3, 2026.
Dr. Lal Pathlabs Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs 874 Cr (+19.6%), EBITDA Rs 280 Cr (32.1% margin), PAT Rs 194 Cr (+27.5%). Strategy: AI diagnostics, rural GraminFit, M&A.
Dr. Lal Pathlabs Q2 FY27 Results: Net Profit ₹193.9 Cr, Up 27.4% YoY
Dr. Lal Pathlabs Ltd reported revenue from operations of ₹873.9 Cr (+19.6% YoY) and net profit of ₹193.9 Cr (+27.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹193.9 Cr · +27.4% YoY